Share price · JAZZ
$247.77 -5.30 (-2.09%) 3M
close as of 2026-11-18 · 24h delayed · vol 722K (0.9x 30-day avg)
1W 1M 3M YTD 1Y 5Y MAX News
Earnings (3) Press (6) Filings (4) Buybacks (2) Insider (19)
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Compare with peers →
Unusual price moves Days when JAZZ's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
3 Nov 2026 +7.1%
30 Oct 2026 +3.9%
Nothing announced by JAZZ that day or the session before.
26 Oct 2026 -3.9%
26 Aug 2026 -4.2%
6 May 2026 +7.7%
25 Feb 2026 +13.2%
Share of unusual movement by asset For each asset, the share of JAZZ's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Asset Event days Share of unusual movement Zanidatamab events and moves 23 Oct 2026 Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 own move +1.1% , next session -4.5% 31 Aug 2026 Phase 3 HERIZON-GEA-01 second interim analysis: ZIIHERA plus chemotherapy improved overall survival versus trastuzumab plus chemotherapy own move +2.4% , next session -3.3% 25 Aug 2026 FDA approval: ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-authorized test own move -0.7% , next session -3.8% 25 Aug 2026 BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer own move -0.7% , next session -3.8% 25 Aug 2026 Jazz Pharmaceuticals: U.S. FDA Approves Ziihera ® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma own move -0.7% , next session -3.8% 27 May 2026 Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA own move -0.8% , next session -2.1% 27 Apr 2026 Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA own move +2.6% , next session +2.8% 21 Apr 2026 Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) own move -0.7% , next session +1.0% 6 Jan 2026 Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit own move -5.9% , next session -2.1% 23 Dec 2025 ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA own move +0.7% , next session -0.3% 17 Dec 2025 Jazz Pharmaceuticals to Participate in Upcoming Investor Events own move -2.0% , next session +1.4% 2 Dec 2025 Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium own move -2.0% , next session -2.6% 17 Nov 2025 Zymeworks: Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera ® own move +19.9% , next session +5.8% 17 Nov 2025 Jazz Pharmaceuticals: Phase 3 Results Support Ziihera ® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma own move +19.9% , next session +5.8% 6 Nov 2025 Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma own move -2.4% , next session -1.9% 23 23% Lurbinectedin events and moves 30 Sep 2026 FDA approves voluntary withdrawal of the Zepzelca second-line SCLC accelerated approval indication own move -0.9% , next session +2.7% 12 Jun 2026 Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer own move -3.2% , next session -1.9% 29 May 2026 EMA/European Commission approval: Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. own move -0.0% , next session +0.6% 21 Apr 2026 Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) own move -0.7% , next session +1.0% 7 Oct 2025 PDUFA date set for Zepzelca plus atezolizumab own move -0.2% , next session -1.4% 2 Oct 2025 FDA approval: ZEPZELCA is an alkylating drug indicated: in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. own move -1.0% , next session +0.7% 2 Oct 2025 FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer own move -1.0% , next session +0.7% 10 Jun 2025 Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer own move -0.2% , next session -1.1% 2 Jun 2025 Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer own move -2.4% , next session +0.5% 23 Apr 2025 Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma own move -1.1% , next session +2.3% 15 Oct 2024 Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer own move +5.4% , next session -2.3% 10 3% Cannabidiol (Epidiolex) (Epidiolex) events and moves 9 Apr 2026 Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting own move +0.2% , next session -0.2% 5 Dec 2025 Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting own move +1.5% , next session -0.7% 19 Mar 2025 Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting own move +0.3% , next session -0.1% 6 Dec 2024 Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting own move -2.3% , next session -0.6% 5 Sep 2024 Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024 own move +0.2% , next session +0.4% 22 Aug 2024 Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies own move +1.8% , next session -2.0% 6 shown from 8 days Dordaviprone events and moves 4 shown from 8 days Cannabidiol (JZP926) events and moves 1 shown from 8 days Calcium, magnesium, potassium and sodium oxybates (Xywav) (Xywav) events and moves 1 shown from 8 days Assets with fewer than 8 event days, together — 3% Other company news (earnings, financing, releases naming no asset) — 28% Sessions with no dated event — 43%
Assets (8 total) 8 Total Assets
7 Approved
0 Phase 3 / Filed
1 Phase 1–2 / Early
13 Diseases
Disease: All diseases (8) Narcolepsy (2) Epilepsy (2) Idiopathic Hypersomnia (1) Developmental and Epileptic Encephalopathies (1) Dravet Syndrome (1) Lennox-Gastaut Syndrome (1) Glioma (1) Small Cell Lung Cancer (1) Acute Myeloid Leukemia (1) Non-Small Cell Lung Cancer (1) Biliary Tract Cancer (1) Breast Cancer (1) Gastric Cancer (1)
Stage: All stages (8) Approved / Phase 4 (7) Phase 3 / Filed (0) Phase 2 Phase 1 / Preclinical
Quick filter: All (8) Narcolepsy (2) Epilepsy (2) Idiopathic Hypersomnia (1) Developmental and Epileptic Encephalopathies (1) Dravet Syndrome (1)
Showing 8 of 8 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved GABA-B receptor Small molecule
Narcolepsy Idiopathic Hypersomnia
Approved GPR55 / TRPV1 / adenosine transport (multi-target) · cannabinoid Small molecule
Epilepsy Developmental and Epileptic Encephalopathies Dravet Syndrome Lennox-Gastaut Syndrome
Approved Mitochondrial caseinolytic protease P (ClpP) · Dopamine D2 receptor Small molecule
Approved Alkylating Drug Small molecule
Approved GABA-B receptor Small molecule
Approved DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II Small molecule
Approved HER2 Multispecific antibody
Non-Small Cell Lung Cancer Biliary Tract Cancer Breast Cancer Gastric Cancer
HER2-Positive Breast Cancer Phase 2/3 Cannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55 · cannabinoid Small molecule
Discontinued programmes (2) Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events (11 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (1) December 2026 (1) Zanidatamab Phase 2 Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer … Est. primary completion 2026-12-31 ·
NCT06695845 ·
CT.gov ↗ What to watch
2027 (3) December 2027 (3) Est. primary completion 2027-12-23 ·
NCT07625280 ·
CT.gov ↗ What to watch
Zanidatamab Phase 2 HER2-positive Breast Cancer, Breast Cancer Est. primary completion 2027-12-29 ·
NCT07102381 ·
CT.gov ↗ What to watch
Lurbinectedin Phase 3 Relapsed Small Cell Lung Cancer Est. primary completion 2027-12-31 ·
NCT06496048 ·
CT.gov ↗ What to watch
2028 (5) January 2028 (1) Lurbinectedin Phase 1/2 Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma Est. primary completion 2028-01-28 ·
NCT05734066 ·
CT.gov ↗ What to watch
April 2028 (1) Zanidatamab Phase 3 Metastatic HER2-positive Breast Cancer Est. primary completion 2028-04-28 ·
NCT06435429 ·
CT.gov ↗ What to watch
June 2028 (1) Dordaviprone Phase 3 H3 K27M, Glioma Est. primary completion 2028-06 ·
NCT05580562 ·
CT.gov ↗ What to watch
August 2028 (1) December 2028 (1) Zanidatamab Phase 3 Biliary Tract Cancer Est. primary completion 2028-12-01 ·
NCT06282575 ·
CT.gov ↗ What to watch
2029 (2) August 2029 (2) Lurbinectedin Phase 2 Extensive-stage Small-cell Lung Cancer Est. primary completion 2029-08-04 ·
NCT07459634 ·
CT.gov ↗ What to watch
Lurbinectedin Phase 3 Leiomyosarcoma Est. primary completion 2029-08-30 ·
NCT06088290 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (17) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
30 September 2026 Withdrawal Lurbinectedin (Zepzelca) FDA approves voluntary withdrawal of the Zepzelca second-line SCLC accelerated approval indication US, FDA · Jazz Pharmaceuticals Ireland, Ltd. ·
Source ↗ 31 August 2026 Topline result Zanidatamab Phase 3 HERIZON-GEA-01 second interim analysis: ZIIHERA plus chemotherapy improved overall survival versus trastuzumab plus chemotherapy 25 August 2026 Approval Zanidatamab FDA approves Ziihera regimens in first-line HER2+ gastroesophageal adenocarcinoma 25 August 2026 FDA action date Zanidatamab PDUFA target date August 25, 2026 3 August 2026 Filing submitted Cannabidiol capsule (JZP926) Jazz reports an NDA submitted for the cannabidiol capsule formulation in currently approved indications (reported 2026-08-03; submission date not disclosed) US, FDA · Jazz Pharmaceuticals ·
Source ↗ August 2026 Approval Zanidatamab FDA updates Boxed Warning on Zanidatamab (BLA761416) June 2026 Topline result Lurbinectedin Phase 3 LAGOON did not meet its overall survival primary endpoint 27 April 2026 Filing accepted Zanidatamab FDA accepts Ziihera sBLA for first-line HER2+ GEA 27 April 2026 Priority review Zanidatamab FDA grants Priority Review to Ziihera sBLA 7 October 2025 FDA action date Lurbinectedin PDUFA date set for Zepzelca plus atezolizumab 2 October 2025 Approval Lurbinectedin FDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC 1 July 2025 Approval Zanidatamab EC conditional marketing authorization for Ziihera in HER2-positive BTC The 12 most recent of 17 past events are shown.
Financial reports Quarterly & interim (16)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2026-Q3 $1.2B $212M $2.0B+ $820M short-term inv. $483M$506M operating cash flow report ↗
View 15 more Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2026-Q2 $1.2B $208M $1.6B+ $580M short-term inv. —$416M operating cash flow report ↗ 2026-Q1 $1.1B $196M $1.8B+ $1.0B short-term inv. —$408M operating cash flow report ↗ 2025-Q3 $1.1B $198M $1.3B —$475M operating cash flow report ↗ 2025-Q2 $1.0B $190M $1.2B $718M$89M operating cash flow report ↗ 2025-Q1 $898M $181M $1.9B $93M$430M operating cash flow report ↗ 2024-Q3 $1.1B $200M $2.2B —$399M operating cash flow report ↗ 2024-Q2 $1.0B $221M $1.4B —$331M operating cash flow report ↗ 2024-Q1 $902M $223M $1.4B $15M$267M operating cash flow report ↗ 2023-Q3 $972M $234M $1.3B —$307M operating cash flow report ↗ 2023-Q2 $957M $209M $1.3B —$297M operating cash flow report ↗ 2023-Q1 $893M $189M $1.2B —$321M operating cash flow report ↗ 2022-Q3 $941M $149M $839M $20M$418M operating cash flow report ↗ 2022-Q2 $933M $139M $711M —$303M operating cash flow report ↗ 2022-Q1 $814M $130M $491M —$209M operating cash flow report ↗ 2021-Q3 $838M $141M $672M $53M$274M operating cash flow report ↗
Annual history (5 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $4.3B $783M $1.4B+ $1.1B short-term inv. $89M$1.4B operating cash flow report ↗
For FY2025, Jazz Pharmaceuticals reported revenue of $4,267.59M, up 4.9% YoY from $4,068.95M, with R&D spend of $782.74M, down 11.5% YoY. Cash and equivalents were $1,391.9M, and the company reported a net loss of $356.15M, with a quarterly net burn of $356.15M.
View 4 more years Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $4.1B $884M $2.4B —$1.4B operating cash flow report ↗ 2023-FY $3.8B $850M $1.5B —$1.1B operating cash flow report ↗ 2022-FY $3.7B $590M $881M $56M$1.3B operating cash flow report ↗ 2021-FY $3.1B $506M $591M $82M$779M operating cash flow report ↗
Insider transactions Open-market activity, trailing 12 months: 0 purchases ($0), 58 sales ($80.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
Tax withholding (21) Open-market sale (13) Option exercise (6)
Date↓ Insider Transaction Shares Price Value Source 2026-11-06 COZADD BRUCE C · director Option exercise 734 $136.18 $100K Form 4 2026-11-06 COZADD BRUCE C · director Option exercise 85,766 $136.18 $11.7M Form 4 2026-11-06 COZADD BRUCE C · director Open-market sale 27,714 $234.91 $6.5M Form 4 2026-11-06 COZADD BRUCE C · director Open-market sale 10,688 $235.82 $2.5M Form 4 2026-11-06 COZADD BRUCE C · director Open-market sale 24,483 $236.84 $5.8M Form 4 2026-11-06 COZADD BRUCE C · director Open-market sale 5,923 $237.39 $1.4M Form 4 2026-11-06 COZADD BRUCE C · director Option exercise (derivative) 734 — — Form 4 2026-11-06 COZADD BRUCE C · director Option exercise (derivative) 85,766 — — Form 4
View 32 more (of 1185 stored) Institutional holders From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 566 reporting institutions held 65.0M shares ($11.5B, 103.6% of shares outstanding).
# Institution Shares Value 1 BlackRock, Inc. 5,591,700 $1.1B 2 VANGUARD PORTFOLIO MANAGEMENT LLC 2,983,242 $564.0M 3 Capital World Investors 2,673,376 $505.4M 4 VANGUARD CAPITAL MANAGEMENT LLC 2,648,333 $500.7M 5 FMR LLC 2,275,762 $430.2M 6 FRANKLIN RESOURCES INC 1,958,940 $370.3M 7 DIMENSIONAL FUND ADVISORS LP 1,895,215 $358.3M 8 STATE STREET CORP 1,891,646 $357.6M 9 EcoR1 Capital, LLC 1,706,469 $322.6M 10 Bank of New York Mellon Corp 1,679,371 $317.5M 11 FULLER & THALER ASSET MANAGEMENT, INC. 1,676,142 $316.9M 12 AMERIPRISE FINANCIAL INC 1,608,476 $304.1M 13 AQR CAPITAL MANAGEMENT LLC 1,338,458 $249.9M 14 MILLENNIUM MANAGEMENT LLC 1,262,511 $238.7M 15 CITADEL ADVISORS LLC 1,259,444 $238.1M